Recon: Pharma industry nears clarity on GDPR application for PV, trials; Investors warier than ever of funding mRNA vax

• Trump administration leaves biotech investors more wary than ever of funding mRNA vaccines (STAT)
• U.S. warning on use of ‘march-in’ rights against Harvard seems like distant threat for pharma (STAT)
• Kennedy’s case against mRNA vaccines collapses under his own evidence (STAT)
• ‘Makes No Sense': Experts Push Back On RFK Jr.’s Doubts About Hepatitis B Vaccine (MedPage Today)
• Drugmakers form new group to lobby on impact of Medicare drug price negotiations (STAT)
• Lilly gets another obesity partner in deal with Superluminal worth up to $1.3B (Endpoints)
• Trump executive order focuses on stockpiling raw materials for 'critical' drugs (Endpoints)

• Lilly to hike UK price of Mounjaro weight-loss drug by 170% (Reuters)
• Swiss Ministers Meet With Roche, Novartis Amid Tariff Crisis (Bloomberg)
• GDPR Clarity For Pharma: Industry Code Nears EU-Wide Approval After Six-Year Journey (Pink Sheet)
• UK Initiative Steps Up Efforts To Tackle Recruitment Bottlenecks In Dementia Trials (Pink Sheet)
• Danish Probe Could Influence Rethink Of Controversial EU Urban Wastewater Rules (Pink Sheet)
• Brazil’s Medtechs Look to Solutions After 50% US Tariff Hit Amid ‘Scenario of Uncertainty’ (Medtech Insight)

• ADHD Medicines Reduce Suicide, Crime Risks in Sweeping Study (Bloomberg)
• Duke scientists seemed to have developed a ‘Holy Grail’ of cancer treatment. Then the truth came out (STAT)
• No Chemo Benefit in Older Women With High-Risk HR-Positive Breast Cancer (MedPage Today)
• Popular Diabetes Drugs Linked to Small Risk of Retinal, Optic Nerve Disorders (MedPage Today)
• GLP-1 Drugs May Hold Benefit in Painful Skin Disease (MedPage Today)
• Early Treatment Shows Benefit in Infants With Presymptomatic Genetic Disease (MedPage Today)
• Schrödinger ends work on blood cancer drug after two patient deaths (Endpoints)
• Fertility startup Gameto raises $44M to fund Phase 3 study of stem cell IVF therapy (Endpoints)
• In the scramble for capital, biotechs turn to royalty deals (Endpoints)
• Sarepta sells Arrowhead stake for cash and to help fulfill milestone payment (Endpoints)
• Vedanta's microbiome therapy fails Phase 2, company lays off 20% (Endpoints)

• OpenAI can’t have it both ways on GPT-5 and health (STAT)
• Japan’s green light for making human embryos from stem cells takes us into uncharted territory (STAT)
• Apple Watch Blood Oxygen Tracker Back in US With Workaround (Bloomberg)
• Whoop Refuses to Pull Blood Pressure Tool After FDA Warning (Bloomberg)
• Shan Jegatheeswaran shares J&J’s vision for AI in the OR (MedTech Dive)

• Brain Autopsies Suggest MIND Diet Reduces Pathology (MedPage Today)
• Daring Foods acquired by one of Australia’s biggest plant-based meat producers (Food Dive)

• Trump Order Gives Political Appointees Review of Scientific Grants (MedPage Today)
• Aluminum in Vaccines Study Won't Be Retracted, Journal Says (MedPage Today)
• Costco Won’t Sell Abortion Pill as Religious Investors Declare Win (Bloomberg)
• CDER White Paper Promotes FDA’s View of the Benefits of Investing in Pharmaceutical Quality (FDA Law Blog)